drugset / Trial / NCT05664750

Study to Compare the Efficacy and Safety of Passive Immunization With TNM002 Injection and Human Tetanus Immunoglobulin as Prophylaxis Against Tetanus

NCT05664750

Phase 3 Completed 675 enrolled Zhuhai Trinomab Pharmaceutical Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

TNM002 Injection is a recombinant fully human native monoclonal antibody (mAb) against tetanus toxin and is currently under development for indication of prophylaxis against tetanus.

Timeline

Start
2022-12-22
Primary completion
2023-03-24
Completion
2023-07-07

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Human tetanus immunoglobulin Protein / enzyme biologic 250 iu Intramuscular
Subject SILTARTOXATUG Monoclonal antibody 10 mg Intramuscular

Indications